Risk factors for developing irAEs are the administration of high doses of ICI (only while using CTLA-4 inhibitors), preexisting autoimmune diseases (3, 106) and obesity (through the proinflammatory metabolic state) (107, 108). Here, CTLA4 is linked to autoimmune disease.